Rationality and Safety of New Monoclonal Antibody Antitumor Drugs Used Clinically in a Tertiary Tumor Hospital

doi:10.19803/j.1672-8629.2021.10.14

Abstract

Abstract: Objective To investigate the clinical applications of new monoclonal antibody antitumor drugs in a hospital and analyze the rationality and safety of related medications in order to provide data for regulation and safe use of novel anticancer drugs. Methods A total of 480 medical records of inpatients who had used novel monoclonal antibody antitumor drugs from January 1, 2019 to December 31, 2020 were randomly chosen from a hospital and the rationality and safety of clinical applications were retrospectively analyzed. Results Among the 480 medical records, there were 125 cases of improper use of medicines, accounting for 26% of the total and involving off-label drug use(27.2%), wrong usage and dosage(41.6%), improper pretreatment drug use(20.0%), and imperfect solvent selection and dosage of solvents (11.2%).There were 362 cases of adverse drug reactions (ADR) found in these medical records. The top three organ-system ADRs were skin mucosal injury (20.8%), infusion related reactions (19.7%) and digestive system injury (14.7%). Conclusion The clinical use of new monoclonal antibody antitumor drugs is imperfect in this hospital. The hospital should regulate and rationally use new antitumor drugs according to the latest clinical guidelines, be alert to their adverse reactions, and ensure the safety and effectiveness of drug use.

Key words: monoclonal antibody, antitumor drugs, rationality, safety, clinical pharmacists

CLC Number:

R73R979.1

WU Hong, LI Xin, HAN Feng. Rationality and Safety of New Monoclonal Antibody Antitumor Drugs Used Clinically in a Tertiary Tumor Hospital[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 960-964.

References

[1] Shi Y, Gan XN, Cai J, et al.Using bibliometrics analysis to explore the global research status and future trends of psychological problems and intervention models of cancer patients[J]. Journal of Chongqing Medical University(重庆医科大学学报), 2021, 46(1): 120-127.
[2] Cox EC, Thornlow DN, Jones MA, et al.Antibody-mediated endocy-tosis of polysialic acid enables intracellular delivery and cytotoxicity of a glycan-directed antibody-drug conjugate[J].Cancer Res, 2019, 4(15): 798-801.
[3] Jeon IS, Yoo JD, Gurung S, et al.Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs[J]. Biomaterials. 2021, 270(5): 685-689.
[4] National Health Commission. Notice of the National Health Commission on the issuance of the administrative measures for the clinical application of anti-tumor drugs (for trial),Guowei medical letter [2020] no. 487 [EB/OL]. (2020-12-22)[2021-03-01]. http://www.nhc.gov.cn/yzygj/s7659/202012/a7600740bed44d1db7015ca5a1be2cc0.html.
[5] Cheng J, Han YX, Wang L, et al.Analysis of 54 cases of adverse reactions of novel anticancer drugs[J]. Chinese Journal of New Drugs(中国新药杂志), 2021, 30(3): 280-284.
[6] Jia JQ, Sun YF, Qin F.Analysis of clinical use of antitumor drugs[J]. Chinese Journal of Drug Evaluation(中国药物评价), 2019, 36(5): 383-387.
[7] Zhao CX, Hu ZW, Cui B.Research progress of monoclonal antibody drugs[J]. Acta Pharmaceutica Sinica(药学学报), 2017, 52(6): 837-847.
[8] Zhang JH, Yang JQ, Luo Y.Mining and evaluation of safety signals for monoclonal anti-tumor representative drugs after marketing[J]. Chinese Journal of New Drugs(中国新药杂志), 2019, 28(13):1654-1660.
[9] George Mantese.Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment[J]. Current Opinion in Gastroenterology, 2019, 35(6): 23-27.
[10] Fu WT, Wang KY, Song CL, et al.Investigation and analysis of off-label use of anti-tumor drugs in our hospital from 2012 to 2014 and its reasonableness evaluation[J]. China Medical Herald(中国医药导报), 2016, 13(8): 146-149.
[11] Su YX, Xue P, Mao Y, et al.Clinical progress of navuliumab in the treatment of non-small cell lung cancer[J].Chinese Journal of Clinical Oncology(中国肿瘤临床), 2020, 47(6): 304-308.
[12] Zhang JF, Liu C, Kai ZX, et al.Clinical significance of programmed death molecule-1 inhibitor navulliumab in the treatment of advanced renal carcinoma[J]. Journal of Modern Urology(现代泌尿外科杂志), 2020, 25(3): 280-284.
[13] Zhou YW, Xia RL, Xiao HL, et al.Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer[J]. International Immunopharmacology, 2021, 9(11): 35-49.
[14] Wu X, Gu Z, Chen Y, et al.Application of PD-1 blockade in cancer immunotherapy[J]. Comput Struct Biotechnol J, 2019, 3(17): 661-674.
[15] Tan JR, Hu CP.Fatal adverse reactions associated with immune checkpoint inhibitors and management strategies[J]. Chinese Journal of Practical Internal Medicine(中国实用内科杂志), 2020, 40(4): 340-344.
[16] Naing A, Hajjar J, Gulley JL, et al.Strategies for improving the management of immune-related adverse events[J]. Journal For Immunotherapy of Cancer, 2020, 8(2): 78-81.